Stay updated on Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page’s displayed software/webpage revision version was updated from v3.5.2 to v3.5.3 without changing any underlying study details.SummaryDifference0.0%

- Check9 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.0%

- Check45 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check74 days agoChange DetectedA minor site revision tag (Revision: v3.4.2) was added, and the previous government funding notice about updates and operations was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check81 days agoChange DetectedA site-wide notice about government funding lapse and NIH operations was added, and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.